FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number 3235-0104 Estimated average burden

				Filed	l pursuant to So or Section 3	ection 16(a) of the Securities Exchange Act of 1934 0(h) of the Investment Company Act of 1940			hours per res	sponse:	0
1. Name and Address of Reporting Person <sup>*</sup> <u>Monia Brett P</u>				2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2012		3. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]					
(Last) (First) (Middle) C/O ISIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT (Street) CARLSBAD CA 92010 (City) (State) (Zip)						4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below)	10% Owner ow) Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year) 01/03/2012 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
						Senior Vice Presi					
				Table	e I - Non-De	rivative Securities Beneficially Owne	d				
1. Title of Security (Instr. 4)						2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership For (D) or Indirect (I)		ature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock					5,073	D					
						vative Securities Beneficially Owned varrants, options, convertible securiti	es)				
1. Title of Derivative Security (Instr. 4)				2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion Exercise Price of Derivative		6. Nature of Indirect Beneficia Ownership (Instr. 5)	1
				Date Exercisable	Expiration Date	Title	Amount or Number of Shares	- Security			
Employee Stock Option (right to buy)				01/02/2008	01/01/2014	Common Stock	18,240	6.81	D		
Employee Stock Option (right to buy)				01/03/2010	01/02/2013	Common Stock	12,031	5.25	D		
Employee Stock Option (right to buy)				01/02/2011	01/01/2014	Common Stock	19,500	11.12	D		-
Employee Stock Option (right to buy)			01/01/2012	12/31/2014	Common Stock	10,000	15.75	D			
Employee Stock Option (right to buy)				01/02/2012 <sup>(1)</sup>	01/01/2015	Common Stock	20,000	15.38	D		
Employee Stock C	Option (right to buy)			01/02/2010 <sup>(2)</sup>	01/01/2016	Common Stock	22,500	14.47	D		
Employee Stock Option (right to buy) 02				02/16/2010 <sup>(3)</sup>	02/15/2016	Common Stock	5,000	14.65	D		
Employee Stock Option (right to buy)				01/04/2011 <sup>(4)</sup>	01/03/2017	Common Stock	22,500	11.27	D		
Employee Stock Option (right to buy)				01/03/2012 <sup>(5)</sup>	01/02/2018	Common Stock	22,600	10.29	D		

## Explanation of Responses:

Logarithmic of 1/2/08 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 2000 Broad-Based Equity Incentive Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/09. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments, at the rate of 5,000 shares per year. The option is exercisable on 1/1/12. Crant of 1/2/08 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1999 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/10. Thereafter, the remaining shares subject to the option vested and became exercisable on 1/2/10. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments, at the rate of 5,625 shares per year. The option is exercisable in 16,406 shares on 1/1/12.

at the rate of 5,625 shares per year. The option is exercisable as to 16,406 shares on 1/1/12. 3. Grant of 2/16/09 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 2/16/10. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments, at the rate of 1,250 shares per year. The option is exercisable as to 13,541 shares on 1/1/12. 4. Grant of 1/4/10 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/4/11. Thereafter, the remaining shares subject to the option vested and became exercisable in 36 equal monthly installments, at the rate of 5,625 shares per year. The option is exercisable as to 10,781 shares on 1/1/12. 5. Grant of 1/3/11 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/3/12. Thereafter, the remaining shares subject to the option vested and become exercisable in 36 equal monthly installments, at the rate of 5,650 shares per year. The option is exercisable as to 0,0781 shares on 1/1/12.

## Remarks:

/s/B. Lynne Parshall, Attorney-In-Fact \*\* Signature of Reporting Person

03/07/2012 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ft(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Stanley T. Crooke and B. Lynne Parshall, signing individually, the undersigned (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Isis Pharmaceuticals, Inc. (Is (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best in The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, ( This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with t

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of January, 2012.

/S/Brett P. Monia